TAM (Treatments and Medicines) NHS Highland
Important: Therapy notes
For urology use.
Important: Formulation and dosage details
Formulation:
Bladder instillation 12·5mg, 81mg (specialist use only)
Other immunomodulating drugs (Formulary)
What's new / Latest updates
Important: Formulation and dosage details
Formulation:
Injection pre-filled syringe (alfa-2a (rbe); Roferon-A®) 3 million units/0·5mL, 4·5 million units/0·5mL, 6 million units/0·5mL, 9 million units/0·5mL (specialist use only)
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk)
MHRA advice: Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions (December 2014) (www.gov.uk)
MHRA advice: Lenalidomide (Revlimid): update on risk of second primary malignancy (December 2014) (www.gov.uk)
MHRA advice: Lenalidomide: risk of thrombosis and thromboembolism (December 2014) (www.gov.uk)
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Capsules 2·5mg, 5mg, 7·5mg, 10mg, 15mg, 20mg, 25mg (hospital use only)
Dosage:
- 441/08: in combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy.
SMC restriction: use in patients who have received at least two prior lines of therapy. - 942/14: for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
- 1096/15: treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
SMC restriction: for use in patients unsuitable for thalidomide-containing regimens. - 2289: as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
- 2281: In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 to 3a).
Important: Therapy notes
Important: Formulation and dosage details
Formulation:
Solution for injection pre-filled syringe (alfa-2a; Pegasys®) 180 micrograms (specialist use only)
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk).
MHRA advice: Pomalidomide (Imnovid): risk of hepatitis B reactivation (May 2016) (www.gov.uk).
MHRA advice: Pomalidomide (Imnovid): risks of cardiac failure, interstitial lung disease and hepatotoxicity (May 2015) (www.gov.uk).
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Capsules 1mg, 2mg, 3mg, 4mg (specialist use only)
Dosage:
As per SMC 972/14: in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Important: Therapy notes
MHRA advice: Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) (May 2020) (www.gov.uk).
MHRA advice: Thalidomide: reduced starting dose in patients older than age 75 years (December 2015) (www.gov.uk).
Risk minimisation materials
Important: Formulation and dosage details
Formulation:
Capsules (Thalidomide Celgene®) 50mg (specialist use only)
Dosage:
As per SMC 525/08: in combination with melphalan and prednisone, as first line treatment of patients with untreated multiple myeloma, aged 65 years or over or ineligible for high dose chemotherapy.